O
CELGZ

OrbiMed’s Celgene Corporation Contingent Value Rights CELGZ Stock Holding History

OrbiMed’s Portfolio CELGZ Stock Details CELGZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-360,900
Closed -$2.9M – 152
2013
Q3 		$2.9M Sell
360,900
-139,100
-28% -$1.07M 0.05% 114
2013
Q2 		$3.65M Buy
+500,000
New +$3.63M 0.08% 110

Other funds holding CELGZ

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
FA
FCG Advisors Chatham, New Jersey $425M AUM 12.09% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
U
UBS Zurich, Switzerland $136B AUM 16.36% 1-Year Est. Return

OrbiMed's CELGZ Position: Q4 2013 in Review

OrbiMed sold out of Celgene Corporation Contingent Value Rights (CELGZ) in Q4 2013, closing a stake of 360,900 shares — an estimated $2.9M sold.

OrbiMed first reported a position in CELGZ in Q2 2013 and held it in 2 quarters. The position peaked at $3.65M in Q2 2013. 25 funds tracked by Wall St. Rank hold CELGZ as of Q4 2013.

  • OrbiMed reported no remaining Celgene Corporation Contingent Value Rights position as of Q4 2013 after selling out during the quarter.
  • OrbiMed sold 360,900 Celgene Corporation Contingent Value Rights shares in Q4 2013, an estimated $2.9M.
  • OrbiMed first reported a position in Celgene Corporation Contingent Value Rights in Q2 2013 and held it in 2 quarters.
  • OrbiMed's Celgene Corporation Contingent Value Rights position peaked at $3.65M in Q2 2013.
  • 25 funds tracked by Wall St. Rank held Celgene Corporation Contingent Value Rights as of Q4 2013.

Based on OrbiMed's 13F filing for Q4 2013, filed 14 Feb 2014.